Latest Healthcare Sector News

EBOS Group Limited reported a steady FY25 with 12% revenue growth and EBITDA in line with guidance, driven by strong healthcare and animal care segments. The company signals confidence with maintained dividends and a positive FY26 outlook.

EBOS Group Limited has reported a 7% decline in revenue and a 21% drop in net profit for FY2025, yet it maintains its final dividend at 61.5 NZ cents per share. The results reflect ongoing cost pressures and restructuring expenses amid a challenging market environment.

Integral Diagnostics Limited (ASX – IDX) reported a robust FY25 performance, boosted by its transformative merger with Capitol Health Limited. The company posted strong revenue and profit growth, declared a 4.0 cent final dividend, and outlined strategic priorities including AI adoption and teleradiology expansion.

Tyro Payments reported modest transaction growth and a 10.6% rise in EBITDA for FY25, while preparing for a CEO change and expanding into new industry verticals.

Australian Clinical Labs reported a 6.4% revenue increase and an 8.7% rise in underlying EBIT for FY25, maintaining disciplined growth and operational efficiency in a complex healthcare environment.

Acrow Limited reports a record FY25 with sales up 23%, driven by an 83% jump in its Industrial Access division, now half of group revenue. Despite soft formwork markets, strategic acquisitions and growth initiatives underpin a confident outlook.

Vitura Health reported a modest revenue increase to $124 million for FY2025, while net profit dipped 5.35% due to margin pressures and investment in new platforms. The company declared a fully franked dividend and highlighted growth in telehealth and medical services.

Vita Life Sciences reported a robust half-year performance with revenue up 15.4% to A$45.5 million and a 12.2% rise in net profit, driven by strong growth in Australia and Southeast Asia. The company also increased its interim dividend to 4.5 cents per share, signaling confidence despite challenges in China.

Ansell Limited reported record FY25 sales and EBIT margins, completing KBU integration ahead of schedule and upgrading synergy targets. The company guides higher adjusted EPS for FY26, fully offsetting US tariff hikes through pricing.

Ansell Limited has announced an unfranked ordinary dividend of USD 0.28 per share for the six months ending June 2025, accompanied by a Dividend Reinvestment Plan available to select shareholders.

Universal Biosensors Inc. has been suspended from ASX trading following the appointment of voluntary administrators, highlighting serious financial distress within the company.

Monash IVF Group reported a 5.6% rise in underlying EBITDA for FY25, navigating a declining Australian IVF market and operational challenges. The company sets a cautious FY26 NPAT guidance of $20-23 million while focusing on regaining market leadership and implementing safety reforms.